Compare KPLT & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPLT | GRDX |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United Kingdom |
| Employees | 87 | 2 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 28.6M |
| IPO Year | N/A | N/A |
| Metric | KPLT | GRDX |
|---|---|---|
| Price | $6.24 | $3.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 6.1K | ★ 56.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.62 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $1.87 |
| 52 Week High | $24.15 | $6.93 |
| Indicator | KPLT | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 39.54 |
| Support Level | $5.89 | $2.01 |
| Resistance Level | $6.79 | $3.65 |
| Average True Range (ATR) | 0.49 | 0.38 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 17.37 | 26.35 |
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.